<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:department>Contracts Office</gtr:department><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1F2CCC33-A16C-432E-B2F2-2AD8828615D3"><gtr:id>1F2CCC33-A16C-432E-B2F2-2AD8828615D3</gtr:id><gtr:firstName>Mervyn</gtr:firstName><gtr:surname>Bibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FJ%2F000CA488"><gtr:id>CD255D39-D23A-485A-A75A-75194D119E5C</gtr:id><gtr:title>Understanding and Exploiting Tunicamycin (Bio)Synthesis to Enable Novel Antibiotics and Inhibitors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/J/000CA488</gtr:grantReference><gtr:abstractText>Tunicamycin inhibits bacterial cell wall biosynthesis by blocking MraY, the enzyme that makes the essential biosynthetic precursor lipid I. This mode of action is different to that of any clinically used antibiotic, and the compound is thus active against a broad range of antibiotic resistant bacterial pathogens. Unfortunately, tunicamycin also inhibits protein N-glycosylation, and is thus toxic to mammals. These two inhibitory activities are believed to reflect different structural characteristics of tunicamycin. 
We have recently, through genome mining of the producing organism Streptomyces chartreusis, discovered the gene cluster for tunicamycin biosynthesis. We have also developed methods for synthesizing key biosynthetic intermediates. We will explore not only the mechanism of formation of the unique tunicamycin structure but also assess the utility of the biosynthetic enzymes to generate novel tunicamycin derivatives. The modular structure of tunicamycin suggests that the inhibitory scaffold may be altered in a systematic way to tune its activity towards and away from the two existing targets. Early results have confirmed that core scaffold modules are active against other nucleotidyl-dependent enzymes. This suggests that analogues may be created that could uncouple existing activities, perhaps allowing eventual use as lead compounds for therapy. This collaborative project will explore tunicamycin biosynthesis, producer immunity, the enzymology (and structures) of key tunicamycin biosynthetic enzymes, the synthesis of tunicamycin analogues, and their activity in screens against target organisms and enzymes</gtr:abstractText><gtr:fund><gtr:end>2015-08-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-08-13</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>55982</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/J/000CA488</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>